Search

Somatrogon

Growth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood … Somatrogon is a long-acting recombinant human growth hormone.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Propantheline

A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

VP025

It is considered to be a systemic anti-inflammatory and neuroprotective agent. … It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease,

Guanfacine

[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release

Sinecatechins

It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components. … Sinecatechins is a botanical drug product for topical use.

Albumin Aggregated

Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.

AX200

Thus, if this drug administered in the acute phase of stroke, the brain’s own protective action is supported. … The expression of the endogenous AX200 protein in the brain is increased after brain damage.

Mafenide

Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … [L36773] In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations.

Nilotinib

A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).